SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 4, 2004
RESPIRONICS, INC.
Delaware | 000-16723 | 25-1304989 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
||
1010 Murry Ridge Lane Murrysville, Pennsylvania |
15668-8525 | |||
(Address of Principal Executive Offices) |
(Zip Code) |
724-387-5200
Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION. | ||||||||
SIGNATURES | ||||||||
INDEX TO EXHIBITS |
Item 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On March 4, 2004, Respironics, Inc. issued a press release announcing that it has acquired 100 percent of the outstanding capital stock of Western Biomedical Technologies (WBT), an Ireland-based company, which owns 100 percent of the outstanding capital stock of Caradyne Limited (Caradyne), also an Ireland-based company. In that press release, Respironics, Inc. also reported that it will not be changing its financial outlook or guidance for fiscal year 2004. A copy of the press release is attached hereto as Exhibit 99.
Exhibits
99
|
Press release, dated March 4, 2004, issued by Respironics, Inc. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RESPIRONICS, INC. | ||||
By: | /s/ Daniel J. Bevevino | |||
Daniel J. Bevevino | ||||
Vice President, and Chief Financial and | ||||
Principal Accounting Officer |
Dated: March 4, 2004
3
INDEX TO EXHIBITS
Exhibit No. | Description | |
99
|
Press release, dated March 4, 2004, issued by Respironics, Inc. |
4